Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


New Developments in Gene Therapy for Muscular Dystrophy

Explore the latest advances in emerging gene therapies for muscular dystrophy diseases.
Richard S. Finkel, MD
Kathryn R. Wagner, MD
Released: July 2, 2020

Hear Dr. Katherine Wagner and Dr. Richard Finkle discuss novel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/muscular-dystrophy-gene-therapy/downloadable-slideset/slides?origin=2

See more neurology topics at: https://www.clinicaloptions.com/internal-medicine/topics/neurology?q&sortBy&sortOrder=asc&page=1


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Sarepta Therapeutics

Related Content

Highlights from gene therapy developments in muscular dystrophy

Released: December 18, 2020

Clinical Care Options (CCO) downloadable audio resource about new developments in gene therapy for muscular dystrophies discussed by expert faculty

Richard S. Finkel, MD Kathryn R. Wagner, MD Released: March 10, 2020

Download slides from Clinical Care Options for current and emerging gene therapy strategies for the treatment of muscular dystrophies

Richard S. Finkel, MD Kathryn R. Wagner, MD Released: February 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.